Induced Pluripotent Stem Cell Production via Protein Extract Reprogramming
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing pluripotent stem cells, such as embryonic stem cells, face ethical concerns due to embryo destruction and low efficiency, and existing alternatives like adult somatic cell reprogramming are inefficient and prone to oncogenesis.
Innovation Solution
Reprogramming adult somatic cells into induced pluripotent stem cells using a protein extract from dedifferentiated stem cells, avoiding embryonic stem cells and viral oncogenes, to generate safe and immunocompatible pluripotent stem cells with high efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If embryonic stem cells are used to produce pluripotent stem cells, then pluripotency is achieved, but ethical problems arise due to embryo destruction
Solution Approach 1:
The invention creates induced pluripotent stem cells (iPSCs) by reprogramming adult somatic cells to copy the pluripotent state of embryonic stem cells without using actual embryos. This is achieved by introducing specific transcription factors (Oct4, Sox2, Klf4, c-Myc) that reset the cellular programming, thereby replicating embryonic stem cell characteristics while avoiding ethical concerns about embryo destruction
Solution Approach 2:
The invention changes the fundamental parameter of cell origin from embryonic to adult somatic cells. By altering the starting material and using reprogramming factors to change the cellular state, the method achieves pluripotency through a different biological pathway that does not involve embryo destruction, thus resolving the ethical contradiction
2Reliability
If adult somatic cells are reprogrammed using viral delivery system with oncogenes, then pluripotent stem cells are generated, but tumorigenicity occurs
Solution Approach 1:
The invention extracts and removes the harmful oncogenic elements from the reprogramming process. Instead of using viral vectors that carry oncogenes, the method uses non-viral delivery systems and carefully controls the expression of reprogramming factors to achieve pluripotency without introducing tumorigenic risk, thereby separating the beneficial reprogramming effect from the harmful oncogenic side effect
Solution Approach 2:
The invention converts the potential harm of oncogene expression into benefit by using controlled, transient expression of reprogramming factors through safe delivery methods. The factors are delivered in a way that achieves the desired pluripotent state while minimizing and eventually eliminating their presence, thus converting a potentially harmful process into a safe and beneficial one
3Reliability
If adult somatic cells are reprogrammed by defined factors, then pluripotent stem cells are produced, but efficiency is low and methodological difficulty arises
Solution Approach 1:
The invention applies preliminary actions to enhance reprogramming efficiency by pre-treating adult somatic cells with specific conditions or factors before introducing the reprogramming mixture. This preparatory step primed the cells to be more receptive to reprogramming, thereby increasing the overall efficiency and reducing methodological difficulties
Solution Approach 2:
The invention introduces intermediary substances or conditions that facilitate the reprogramming process. These intermediaries act as bridges between the adult somatic cell state and the pluripotent state, making the transition more efficient and easier to control, thereby addressing the low efficiency and methodological challenges
Data Source
AI summary
The present invention provides a method for producing customized pluripotent stem cells. Specifically, the present invention comprises following steps: extracting proteins from any of the dedifferentiated stem cells or induced pluripotent stem cells, the said dedifferentiated or pluripotent stem cells being prepared by any known method; introducing the protein extract into the adult somatic cells; and culturing the adult somatic cells to produce pluripotent stem cells having the same pluripotency as that of embryonic stem cells. In addition, pluripotent stem cells produced according to the present method and cell therapeutics comprising the same are provided. The method allows pluripotent stem cells to be produced very easily and at a significantly higher yield, compared to typical methods.